Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CHKA | P35790 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906769 | 0.84 | SLC6A4 (0.66) | HRH3KCNH2CHKAMETDAO | |
| SCHEMBL18889390 | 0.83 | KCNH2 (0.53) | HRH3KCNH2CHKAMETDAO | |
| Hydrochloric Acid SCHEMBL17444676 | 0.83 | SLC6A4 (0.64) | HRH3KCNH2CHKAMETDAO | |
| SCHEMBL17444603 | 0.82 | KCNH2 (0.52) | HRH3KCNH2CHKAMETHTR1A | |
| SCHEMBL27458564 | 0.77 | HRH3 (0.49) | HRH3KCNH2CHKAMETDAO | |
| SCHEMBL17444664 | 0.76 | KCNH2 (0.48) | HRH3KCNH2CHKAMET | |
| SCHEMBL13499600 | 0.75 | CHKA (0.90) | HRH3KCNH2CHKAMETSLC6A4 | |
| SCHEMBL3846360 | 0.75 | DAO (0.54) | HRH3KCNH2CHKAMETDAO | |
| SCHEMBL27459776 | 0.73 | HRH3 (0.48) | HRH3KCNH2CHKAMETDAO | |
| SCHEMBL4020874 | 0.73 | DAO (0.56) | HRH3KCNH2CHKAMETDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | HRH3 1845/4885KCNH2 4403/4885CHKA 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.